SCHEMBL21865751

SCHEMBL21865751

Cc1cc(OC(F)(F)F)cc([N+](=O)[O-])c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.46
TSHR P16473 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 5/20 0.39
TDP1 Q9NUW8 3/20 0.39
GPR35 Q9HC97 1/20 0.38
FFAR4 Q5NUL3 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MITF O75030 1/20 0.36
TXNRD1 Q16881 2/20 0.36
CCR6 P51684 1/20 0.36
HSD17B10 Q99714 1/20 0.35
CYP3A4 P08684 2/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
HIF1A Q16665 1/20 0.35
TXNRD3 Q86VQ6 1/20 0.35
TXNRD2 Q9NNW7 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10976593 0.85 ALDH1A1 (0.37) CYP1A2TSHRSMN1; SMN2ALDH1A1TDP1
SCHEMBL18299389 0.84 ALDH1A1 (0.36) CYP1A2TSHRSMN1; SMN2ALDH1A1TDP1
SCHEMBL18299235 0.84 MAPT (0.44) CYP1A2TSHRSMN1; SMN2ALDH1A1TDP1
SCHEMBL26103584 0.80 PDGFRB (0.45) TSHRSMN1; SMN2ALDH1A1TDP1MEN1
SCHEMBL26099615 0.80 TSHR (0.48) TSHRSMN1; SMN2ALDH1A1TDP1MEN1
SCHEMBL2540815 0.80 ALDH1A1 (0.50) TSHRSMN1; SMN2ALDH1A1FFAR4MEN1
SCHEMBL13807644 0.80 MAPT (0.49) TSHRSMN1; SMN2ALDH1A1FFAR4MEN1
SCHEMBL31714528 0.80 ALDH1A1 (0.50) TSHRSMN1; SMN2ALDH1A1FFAR4MEN1
SCHEMBL15189277 0.78 FFAR4 (0.42) CYP1A2FFAR4PTGS1PTGS2MAPT
SCHEMBL9369652 0.77 GPR35 (0.50) CYP1A2SMN1; SMN2ALDH1A1TDP1GPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3636643-A1 NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES AbbVie Inc. (US) 2020-04-15 EP disclosed